CASI Net Income Applicable To Common Shares from 2010 to 2025
| CASI Stock | USD 1.25 0.03 2.46% |
Net Loss | First Reported 2000-03-31 | Previous Quarter -10.2 M | Current Value -10.2 M | Quarterly Volatility 4.8 M |
Check CASI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CASI Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 795.3 K, Selling General Administrative of 24.8 M or Other Operating Expenses of 71.6 M, as well as many indicators such as Price To Sales Ratio of 1.45, Dividend Yield of 0.0106 or PTB Ratio of 22.28. CASI financial statements analysis is a perfect complement when working with CASI Pharmaceuticals Valuation or Volatility modules.
CASI | Net Income Applicable To Common Shares | Build AI portfolio with CASI Stock |
Latest CASI Pharmaceuticals' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of CASI Pharmaceuticals over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. CASI Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CASI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
CASI Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (23,497,816) | |
| Geometric Mean | 17,415,766 | |
| Coefficient Of Variation | (67.42) | |
| Mean Deviation | 14,262,645 | |
| Median | (26,202,308) | |
| Standard Deviation | 15,843,128 | |
| Sample Variance | 251T | |
| Range | 42.5M | |
| R-Value | (0.80) | |
| Mean Square Error | 96.7T | |
| R-Squared | 0.64 | |
| Significance | 0.0002 | |
| Slope | (2,663,327) | |
| Total Sum of Squares | 3765.1T |
CASI Net Income Applicable To Common Shares History
About CASI Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as CASI Pharmaceuticals' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although CASI Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Loss | -33 M | -34.6 M |
Currently Active Assets on Macroaxis
When determining whether CASI Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CASI Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Casi Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Casi Pharmaceuticals Stock:Check out the analysis of CASI Pharmaceuticals Correlation against competitors. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.54) | Revenue Per Share | Quarterly Revenue Growth 0.83 | Return On Assets | Return On Equity |
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.